Form 8-K

8-K — Amneal Pharmaceuticals, Inc.

Accession: 0001140361-26-032014

Filed: 2026-08-10

Period: 2026-08-10

CIK: 0001723128

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Entry into a Material Definitive Agreement

Item: Completion of Acquisition or Disposition of Assets

Item: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Item: Unregistered Sales of Equity Securities

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ef20079825_8k.htm (Primary)

EX-10.1 — EXHIBIT 10.1 (ef20079825_ex10-1.htm)

EX-10.2 — EXHIBIT 10.2 (ef20079825_ex10-2.htm)

EX-99.1 — EXHIBIT 99.1 (ef20079825_ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: ef20079825_8k.htm · Sequence: 1

false000172312800017231282026-08-102026-08-10

UNITED

STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 10, 2026

AMNEAL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-38485

93-4225266

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

400 Crossing Blvd

Bridgewater, NJ 08807

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (908)

947-3120

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following

provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A Common Stock, par value $0.01 per share

AMRX

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2

of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised

financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Introductory Note

This Current Report on Form 8-K (this “Report”) is being filed in connection with the completion of the transactions contemplated by the previously

announced Membership Interest Purchase Agreement, dated as of April 21, 2026 (as it may be amended from time to time, the “Purchase Agreement”), by and among Amneal Pharmaceuticals, Inc., a Delaware corporation (“Amneal”), Kashiv BioSciences, LLC

(“Kashiv”), KB Seller Representative, LLC (the “Seller Representative”) and the equityholders of Kashiv named therein (the “Sellers”). On August 10, 2026 (the “Closing Date”), pursuant to the Purchase Agreement, Amneal Pharmaceuticals LLC, a

Delaware limited liability company and wholly owned subsidiary of Amneal (“Amneal LLC”), acting pursuant to the terms and conditions of a previously executed assignment and assumption agreement between it, Amneal, Kashiv and the Seller

Representative, purchased from the Sellers, and the Sellers sold, conveyed, assigned, transferred and delivered to Amneal LLC, 100% of the issued and outstanding membership interests of Kashiv (the “Acquisition”). Pursuant to the Purchase

Agreement, at the closing of the Acquisition (the “Closing”), (i) Amneal LLC was required to pay to the Sellers $375,000,000 in cash, subject to certain purchase price adjustments including for cash, the funding of operations between signing and

closing (subject to a specified cap, calculated on the basis of the period from the date of the Purchase Agreement until the Closing), indebtedness, transaction expenses and working capital fluctuations (relative to a target), and (ii) Amneal was

required to issue to the Sellers 28,942,108 shares of its Class A common stock, par value $0.01 per share, subject to adjustments for fractional shares. The Sellers will also be eligible to receive up to an additional $350,000,000 in potential

contingent payments upon the achievement of certain regulatory milestones in the United States for up to six designated Kashiv product candidates. In addition, during the 12-year period following the Closing, the Sellers will be eligible to receive

certain potential contingent royalty payments equal to 25% of the amount by which annual aggregate gross profits for certain products exceed specified gross profit hurdle amounts for the corresponding annual royalty period.

As previously reported, certain of the Sellers are affiliates of the Amneal Group (as defined in Amneal’s proxy statement for its 2026 annual meeting of

stockholders, which was filed with the Securities and Exchange Commission (the “SEC”) on March 25, 2026).

The foregoing description of the Purchase Agreement and the Acquisition do not purport to

be complete and are qualified in their entirety by reference to the full text of the Purchase Agreement, a copy of which was filed as Exhibit 2.1 to the Current Report on Form 8-K filed by Amneal on April 22, 2026 and is incorporated herein by reference.

Item 1.01

Entry into a Material Definitive Agreement.

The information set forth under the Introductory Note of this Report is incorporated into this Item 1.01 by reference.

First Amendment to the Third Amended and Restated

Stockholders Agreement

In connection with the consummation of the Acquisition, on the Closing Date, Amneal entered into a First Amendment to the Third Amended and Restated

Stockholders Agreement (the “Stockholders Agreement Amendment”) with Vikram Patel, in his capacity as the Amneal Group Representative (as defined in the Third Amended and Restated Stockholders Agreement, dated November 7, 2023, by and among Amneal,

Amneal Intermediate Inc., Amneal LLC, and the other parties named therein (the “Stockholders Agreement”)), pursuant to which Amneal and the Amneal Group Representative agreed, among other things, to amend the definition of “Amneal Group” and “Amneal

Group Member” (in each case, as defined in the Stockholders Agreement), and to clarify that the Stock Consideration (as defined below) issued to the members of the Amneal Group in connection with the Acquisition will be included in the number of

shares owned by the Amneal Group for all purposes of the Stockholders Agreement.

The foregoing description of the Stockholders Agreement Amendment does not purport to be complete and is qualified in its entirety by reference to the full

text of the Stockholders Agreement Amendment, which is attached hereto as Exhibit 10.1.

Amendment No. 4 to the Term Loan Credit Agreement

On August 10, 2026, Amneal LLC and certain of Amneal LLC’s subsidiaries, as guarantors, entered into that certain Amendment No. 4 to Term Loan Credit

Agreement (the “New Incremental Term Loan Amendment”) with JPMorgan Chase Bank, N.A., as administrative agent (the “Agent”), and the other lenders party thereto consenting to the New Incremental Term Loan Amendment. The New Incremental Term Loan

Amendment amends certain terms in that certain Term Loan Credit Agreement, dated as of November 14, 2023 (as amended, restated, supplemented or otherwise modified prior to the date hereof, the “Credit Agreement”; the Credit Agreement, as amended by

the New Incremental Term Loan Amendment, the “Amended Credit Agreement”), by and among Amneal LLC, certain of Amneal LLC’s subsidiaries party thereto as guarantors, the lenders party thereto and the Agent. Pursuant to the New Incremental Term Loan

Amendment, Bank of America, N.A. made an Incremental Term Loan (as defined in the Amended Credit Agreement) (the “New Incremental Term Loan”) to Amneal LLC on the Amendment No. 4 Effective Date (as defined in the New Incremental Term Loan Amendment)

in an aggregate principal amount of $350,000,000 in the form of an increase in the aggregate principal amount of outstanding Amendment No. 3 Term Loans (as defined in the Amended Credit Agreement), the proceeds of which were used as a portion of the

consideration for the Acquisition.

The foregoing description of the New Incremental Term Loan Amendment does not purport to be complete and is qualified in its entirety by reference to the

full text of the New Incremental Term Loan Amendment, which is attached hereto as Exhibit 10.2.

Item 2.01

Completion of Acquisition or Disposition of Assets.

The information set forth in the Introductory Note of this Report is incorporated into this Item 2.01 by reference.

Item 2.03

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth in the Introductory Note and Item 1.01 of this Report is incorporated into this Item 2.03 by reference.

Item 3.02

Unregistered Sales of Equity Securities.

The information set forth in the Introductory Note of this Report is incorporated into this Item 3.02 by reference. Pursuant to the Purchase Agreement,

upon the Closing, Amneal issued to the Sellers 28,942,098 shares of its Class A Common Stock, par value $0.01 per share (as adjusted downward for fractional shares pursuant to the Purchase Agreement, the “Stock Consideration”). The issuance of the

Stock Consideration to the Sellers was made in reliance upon the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), provided by Section 4(a)(2) thereof as a transaction by an issuer not

involving any public offering. The Sellers represented to Amneal that they are “accredited investors” as defined in Rule 501 of the Securities Act and that the securities are being acquired for investment purposes and not with a view to, or for

sale in connection with, any distribution thereof. Pursuant to the Purchase Agreement, Amneal has agreed to file with the SEC a registration statement on Form S-3 to provide for the public resale of the Stock Consideration by the later of (i) 30

days following the Closing Date and (ii) 10 business days following the receipt by Amneal of information reasonably required from the Sellers to be included or incorporated by reference in such registration statement.

Item 7.01

Regulation FD Disclosure.

On the Closing Date, Amneal issued a press release announcing the closing of the Acquisition. A copy of the press release is attached as Exhibit 99.1

hereto.

Item 9.01

Financial Statements and Exhibits.

(a) Financial statements of businesses or funds acquired.

Amneal intends to file the financial statements of Kashiv required by Item 9.01(a) by amendment to this Report no later than 71 calendar days following the

date that this Report is required to be filed.

(b) Pro forma financial information.

Amneal intends to file the pro forma financial information relating to the Acquisition required by Item 9.01(b) by amendment to this Report no later than 71

calendar days following the date of this Report is required to be filed.

(d)

Exhibits

Exhibit No.

Description

2.1

Membership Interest Purchase Agreement, dated as of April 21, 2026, by and among Amneal Pharmaceuticals, Inc., Kashiv BioSciences, LLC, KB Seller

Representative, LLC and the equityholders of Kashiv named therein (incorporated by reference to Exhibit 2.1 to Amneal’s Current Report on Form 8-K filed on April 22, 2026).

10.1

First Amendment to the Third Amended and Restated Stockholders Agreement by and among Amneal, Amneal Intermediate Inc., Amneal LLC, and the other

parties named therein.

10.2

Amendment No. 4 to Term Loan Credit Agreement by and among Amneal LLC, certain of Amneal LLC’s subsidiaries, as guarantors, the Lenders from time

to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent.

99.1

Press release issued August 10, 2026.

104

The cover page from this Report, formatted in iXBRL (Inline eXtensible Business Reporting Language).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its

behalf by the undersigned hereunto duly authorized.

Date: August 10, 2026

AMNEAL PHARMACEUTICALS, INC.

By:

/s/ Jason B. Daly

Name:

Jason B. Daly

Title:

Executive Vice President, Chief Legal Officer and

Corporate Secretary

EX-10.1 — EXHIBIT 10.1

EX-10.1

Filename: ef20079825_ex10-1.htm · Sequence: 2

Exhibit 10.1

Execution Version

FIRST AMENDMENT TO THE THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT

THIS FIRST AMENDMENT TO THE THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this “Amendment”),

is entered into as of August 10, 2026 (the “Execution Date”), by and among Amneal Pharmaceuticals, Inc., a Delaware corporation (the “Company”),

Vikram Patel, in his capacity as the Amneal Group Representative (the “Amneal Group Representative”) and the other Persons set forth under the heading “New Amneal Group Members” on the

signature pages hereto (the “New Amneal Group Members”).

WHEREAS, the Company and the Amneal Group Representative are party to that certain Third Amended and Restated Stockholders Agreement (the “Stockholders Agreement”), dated November 7, 2023, by and among the Company, Amneal Intermediate Inc., a Delaware corporation, Amneal Pharmaceuticals LLC, a Delaware limited liability company,

and the other parties named therein;

WHEREAS, the Company and the Amneal Group Representative desire to amend the Stockholders Agreement in order to make certain changes to the

definitions therein;

WHEREAS, pursuant to Section 7.9 of the Stockholders Agreement, the Stockholders Agreement may be amended by a written instrument signed by the

Company and the Amneal Group Representative; provided, that any material amendment or modification of the Stockholders Agreement shall require the prior written consent of the Conflicts

Committee;

WHEREAS, the Conflicts Committee has delivered prior written consent to this Amendment; and

WHEREAS, unless otherwise defined herein, capitalized terms shall have the meanings ascribed to them in the Stockholders Agreement.

NOW, THEREFORE, for valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto hereby amend the

Stockholders Agreement as follows:

The definition of “Amneal Group” is hereby amended and restated in its entirety to mean, collectively, the Persons listed on Schedule A to

this Amendment; provided, that the “Amneal Group” shall include any Person to whom shares of Company Common Stock are validly Transferred in accordance with Section 4.1(c) of the

Stockholders Agreement after the Execution Date (provided, that such transferee shall, prior to any such Transfer, have agreed in a writing reasonably acceptable to the Company to be

bound by the terms of the Stockholders Agreement as a party thereto in the position of an Amneal Group Member).

The definition of “Amneal Group Member” is hereby amended and restated in its entirety to mean any of the Persons listed on Schedule A to

this Amendment; provided, that any Person to whom shares of Company Common Stock are validly Transferred in accordance with Section 4.1(c) of the Stockholders Agreement after the

Execution Date shall be deemed to be an “Amneal Group Member” (provided, that such transferee shall, prior to any such Transfer, have agreed in a writing reasonably acceptable to the

Company to be bound by the terms of the Stockholders Agreement as a party thereto in the position of an Amneal Group Member).

The Amneal Group Representative represents and warrants that (i) he is the current, duly authorized Amneal Group Representative, (ii) he, in his capacity as the Amneal Group Representative, has the

authority to enter into this Amendment on behalf of each of the Amneal Group Members as of immediately prior to the Execution Time and, if executed by the Company, this Amendment will be binding on such Amneal Group Members, (iii) as of the

Execution Time, each of the Persons listed on Schedule A to this Amendment beneficially owns outstanding shares of the Company Common Stock and (iv) as of the Execution Time, the

Amneal Group (as such term is amended by this Amendment) collectively beneficially owns no less than ten percent (10%) of the outstanding shares of the Company Common

Stock.

The Company represents and warrants that (i) the Conflicts Committee has delivered prior written consent to this Amendment and (ii) the Company has all requisite corporate power and authority to

execute and deliver this Agreement, and, if executed by the other parties hereto, this Amendment will be binding on the Company.

The New Amneal Group Members hereby agree to comply with and be bound by all the terms of the Stockholders Agreement, as amended by this Amendment, as a party thereto in the position of an Amneal

Group Member in the same capacity as if the New Amneal Group Members were original parties thereto in such capacity.

All references in the Stockholders Agreement to “New York Stock Exchange” are hereby deleted and replaced with “Nasdaq Stock Market”.

All references in the Stockholders Agreement to “NYSE” are hereby deleted and replaced with “Nasdaq”.

For the avoidance of doubt, all shares of Company Common Stock that are issued to Amneal Group Members (as such term is amended by this Amendment) pursuant to the Membership Interest Purchase

Agreement, dated as of April 21, 2026, by and among the Company, Kashiv BioSciences, LLC, and the other parties named therein (the “MIPA”) in connection with the Closing (as defined

in the MIPA) shall be included in the number of shares of Company Common Stock beneficially owned by the Amneal Group for all purposes of the Stockholders Agreement (including, without limitation, for purposes of the application of the

definition of Registrable Shares other than with respect to the first sentence of Section 5.1 of the Stockholders Agreement).

All references in the Stockholders Agreement to the “Shelf Registration Statement” shall hereinafter include, in addition to the post-effective Amendment to the Registration Statement on Form S-3

(File No. 333-263225), the S-3 Shelf (as such term is defined in MIPA).

10.

The definition of the “Amneal Group Representative” is hereby amended by replacing “Padmesh Patel” with “Vikram Patel”.

11.

All references in the Stockholders Agreement to “Class A Common Stock” shall mean the Company Common Stock.

12.

Any shares of Company Common Stock that are registered and validly Transferred by Amneal Group Members pursuant to the S-3 Shelf (as defined in the MIPA), when effective under the Securities Act,

shall be deemed to be Transferred pursuant to Section 4.1(b)(i)(A) of the Stockholders Agreement.

13.

On and after the Execution Date, each reference in the Stockholders Agreement to “this Agreement,” “hereunder,” “hereof,” “herein” or words of like import referring to the Stockholders Agreement,

shall mean and be a reference to the Stockholders Agreement as amended by this Amendment.

14.

Except as specifically amended by this Amendment, the Stockholders Agreement shall remain in full force and effect and is hereby ratified and confirmed.

15.

The execution, delivery and performance of this Amendment shall not, except as expressly provided herein, constitute a waiver of any provision of, or operate as a waiver of any right, power, or

remedy of any party under the Stockholders Agreement.

16.

The parties specifically understand and agree that the changes to the Stockholders Agreement by this Amendment are intended to alter certain provisions of the Stockholders Agreement, and that the

matters set forth in this Amendment shall be controlling over those provisions of the Stockholders Agreement which they replace, which shall be treated as superseded.

17.

This Amendment may be executed by electronic signatures (such as Docusign) in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed and

delivered shall be deemed an original, but all such counterparts together shall constitute but one and the same instrument; signature pages may be detached from multiple separate counterparts and attached to a single counterpart so that all

signature pages are physically attached to the same document.

18.

This Amendment shall become effective upon the Execution Date.

[Signature Page Follows]

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed on the date first written above.

AMNEAL PHARMACEUTICALS, INC.

By:

/s/ Jason B. Daly

Name: Jason B. Daly

Title: Executive Vice President, Chief Legal Officer & Corporate Secretary

AMNEAL GROUP REPRESENTATIVE:

By:

/s/ Vikram Patel

Name: Vikram Patel

New Amneal Group Members

CKR INVESTMENTS, LLC

By:

/s/ Chirag Patel

Name: Chirag Patel

Title: General Manager

CKR DYNASTY, LLC

By:

/s/ Chintu Patel

Name: Chintu Patel

Title: General Manager

SHIVKAN HOLDINGS, LLC

By:

/s/ Chintu Patel

Name: Chintu Patel

Title: General Manager

SHIVKAN DYNASTY, LLC

By:

/s/ Chirag Patel

Name: Chirag Patel

Title: General Manager

[Signature Page to First Amendment to Third A&R Stockholders Agreement]

ROCK NOLA, LLC

By:

TUP ONE, LLC

By:

/s/ Tushar Patel

Name: Tushar Patel

Title: Manager

NP INVESTOR GROUP, LLC

By:

/s/ Rishi Reddy

Name: Rishi Reddy

Title: Manager

ARJUN TARSADIA TRUST

By:

/s/ Nilesh Madhav

Name: Nilesh Madhav

Title: Trustee

GLI THREE, LLC

By:

/s/ Edward G. Coss

Name: Edward G. Coss

Title: Manager

CEPHEID CAPITAL, LLC

By:

/s/ Gautam Patel

Name: Gautam Patel

Title: Manager

ANANTYA CAPITAL, LLC

By:

/s/ Vikram Patel

Name: Vikram Patel

Title: Manager

Schedule A

(Amneal Group)

Pre-Existing Amneal Group Members

THE ANISH CHETAN PATEL GIFT TRUST

THE MANSI CHETAN PATEL GIFT TRUST

THE AMAN DIPAN PATEL GIFT TRUST

THE BHAVIN NARENDRA PATEL GIFT TRUST

THE CHINTU PATEL REVOCABLE TRUST

THE CHIRAG PATEL REVOCABLE TRUST

EDWARD G COSS FAMILY TRUST

THE FALGUNI PATEL REVOCABLE TRUST

THE GREENE FAMILY TRUST

10.

GREG & NOLA CASSERLY FAMILY TRUST

11.

THE LUCE FAMILY TRUST

12.

THE SUNIL PATEL FAMILY TRUST

13.

PADMESH M PATEL FAMILY TRUST

14.

AP-1 TRUST

15.

AP-2 TRUST

16.

AP-3 TRUST

17.

AP-5 TRUST

18.

AP-7 TRUST

19.

AP-9 TRUST

20.

DIPAN PATEL LIVING TRUST

21.

THE PRITI PATEL REVOCABLE TRUST

22.

PATEL FAMILY TRUST

23.

THE FALCON TRUST

24.

THE MAYUR PATEL LEGACY TRUST

25.

THE PUJA PATEL TRUST

26.

THE ISHANI PATEL TRUST

27.

THE NIAM PATEL TRUST

28.

TI SIE 2, LLC (successor in interest to Tushar Patel Family Trust)

29.

THE T-TWELVE LEGACY TRUST

30.

B.U. PATEL FAMILY TRUST

31.

GAUTAM PATEL

32.

VIKRAM PATEL

33.

KANU PATEL

34.

TEJASH AND SUNITA PATEL FAMILY TRUST

New Amneal Group Members

35.

CKR INVESTMENTS, LLC

36.

CKR DYNASTY, LLC

37.

SHIVKAN HOLDINGS, LLC

38.

SHIVKAN DYNASTY, LLC

39.

ROCK NOLA, LLC

40.

NP INVESTOR GROUP, LLC

41.

ARJUN TARSADIA TRUST

42.

GLI THREE, LLC

43.

CEPHEID CAPITAL, LLC

44.

ANANTYA CAPITAL, LLC

EX-10.2 — EXHIBIT 10.2

EX-10.2

Filename: ef20079825_ex10-2.htm · Sequence: 3

Exhibit 10.2

Execution Version

AMENDMENT NO. 4 TO TERM LOAN CREDIT AGREEMENT

AMENDMENT NO. 4 TO TERM LOAN CREDIT AGREEMENT, dated as of August 10, 2026 (this “Amendment”),

to the Term Loan Credit Agreement, dated as of November 14, 2023 (as amended, restated, supplemented or otherwise modified from time to time prior to the date hereof, the “Existing Credit Agreement”; as amended by this Amendment and further defined below, the “Amended Credit Agreement”), by

and among AMNEAL PHARMACEUTICALS LLC, a Delaware limited liability company (the “Borrower”), the Lenders from time to time party thereto and JPMORGAN CHASE BANK, N.A., as

administrative agent and collateral agent (in such capacities, the “Administrative Agent”).

W I T N E S S E T H:

WHEREAS, the Borrower wishes

to incur Incremental Term Loans pursuant to Section 2.18 of the Existing Credit Agreement (the “New Incremental Term Loans”) in the form of an increase in the aggregate

principal amount of outstanding Amendment No. 3 Term Loans, the proceeds of which will be used to finance a portion of the consideration for the Borrower’s acquisition (the “Acquisition”)

of 100% of the membership interests in Kashiv BioSciences, LLC (the “Target”) pursuant to that certain Membership Interest Purchase Agreement, dated as of April 21, 2026, by

and among Amneal Pharmaceuticals, Inc., the Target, certain equity holders of the Target and the other parties thereto (as amended, restated, supplemented or otherwise modified from time to time, the “Acquisition Agreement”), with any additional proceeds being available for general corporate purposes;

WHEREAS, the Borrower has

requested that Bank of America, N.A. (in such capacity, the “New Incremental Term Lender”) commit to make a New Incremental Term Loan to the Borrower on the Amendment No. 4

Effective Date (as defined below) in an aggregate principal amount of $350,000,000 (the “New Incremental Term Loan Commitment”);

WHEREAS, the New Incremental

Term Lender is willing to make the New Incremental Term Loan to the Borrower on the terms and conditions set forth herein on the Amendment No. 4 Effective Date;

WHEREAS, pursuant to Section

2.18(5) of the Existing Credit Agreement, the Borrower, the Administrative Agent and the applicable Incremental Lenders (it being agreed that the New Incremental Term Lender constitutes the only initial Incremental Lender with respect to the New

Incremental Term Loans) may, without the consent of any other Lenders, enter into an Incremental Facility Amendment to effect such amendments to the Loan Documents as may be necessary or appropriate, in the reasonable opinion of the Administrative

Agent and the Borrower, to effect the provisions of Section 2.18 of the Existing Credit Agreement and to make the New Incremental Term Loans fungible (including for tax purposes) with the existing Amendment No. 3 Term Loans;

WHEREAS, each of Bank of

America, N.A. (the “Lead Left Amendment No. 4 Lead Arranger”), TPG Capital BD, LLC, JPMorgan Chase Bank, N.A., Truist Securities, Inc., MUFG Bank, Ltd., Goldman Sachs Bank USA,

Citigroup Global Markets Inc., Wells Fargo Securities, LLC, Barclays Bank PLC, HSBC Securities (USA) Inc. and Royal Bank of Canada have each agreed to act as joint lead arrangers and joint bookrunners for the New Incremental Term Loans and this

Amendment (collectively, the “Amendment No. 4 Lead Arrangers”);

NOW, THEREFORE, in

consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

ARTICLE I

Definitions

Section 1.1. Definitions

Capitalized terms used herein but not otherwise defined herein shall have the meanings given such terms in the Amended Credit Agreement (as defined

below).

ARTICLE II

New Incremental Term Loans

Section 2.1. New Incremental Term Loans

On the terms and subject to the conditions set forth herein, the New Incremental Term Lender agrees to make the New Incremental Term Loan to the

Borrower on the Amendment No. 4 Effective Date, in an aggregate principal amount equal to the New Incremental Term Loan Commitment. The terms of the New Incremental Term Loan shall be as set forth in Section 2.3 below. The New Incremental Term Loan

Commitment of the New Incremental Term Lender shall automatically terminate after giving effect to the funding of the New Incremental Term Loan on the Amendment No. 4 Effective Date. Amounts repaid or prepaid in respect of the New Incremental Term

Loan may not be reborrowed.

Section 2.2. Use of Proceeds.

The Borrower shall use the proceeds of the New Incremental Term Loan solely for the purposes set forth in the recitals hereto.

Section 2.3. Other Terms of New Incremental Term Loans. The New Incremental Term Loan shall constitute an Incremental Term Loan in the form of additional Amendment No. 3 Term Loans for all

purposes of the Amended Credit Agreement and the other Loan Documents and shall, except as otherwise set forth herein, have terms that are identical to the terms of the Amendment No. 3 Term Loans outstanding under the Existing Credit Agreement

immediately prior to the Amendment No. 4 Effective Date (the “Existing Term Loans”) (including with respect to maturity, prepayments, interest and amortization (except as set

forth below), but not with respect to use of proceeds and conditions to funding) and shall be fungible with the Existing Term Loans. In furtherance of, and not in limitation of the foregoing:

(a) as

of the Amendment No. 4 Effective Date, Section 2.06(1) of the Existing Credit Agreement shall be amended and restated in its entirety as follows:

“The Borrower will repay to the Administrative Agent for the ratable account of the Lenders on the last Business Day of each fiscal quarter of the

Borrower, commencing with the last Business Day of the fiscal quarter of the Borrower ending on December 31, 2026, an aggregate principal amount of Amendment No. 3 Term Loans equal to 0.25% of the aggregate principal amount of the Amendment No. 3

Term Loans outstanding on the Amendment No. 4 Effective Date, which payments will be reduced as a result of the application of prepayments in accordance with the order of priority set forth in Section 2.07 or 2.08, as applicable (each such date being

referred to as an “Amendment No. 3 Term Loan Installment Date”)”

(b) The

New Incremental Term Loan shall be made as a single Term Benchmark Borrowing, with an initial Interest Period that commences on the Amendment No. 4 Effective Date and ends on the last day of the Interest Period applicable to the Existing Term

Loans at such time. During such initial Interest Period, the Adjusted Term SOFR Rate applicable to the New Incremental Term Loans shall be the same Adjusted Term SOFR Rate applicable to the Existing Term Loans immediately prior to the Amendment

No. 4 Effective Date.

and after the Amendment No. 4 Effective Date, the Existing Term Loans and the New Incremental Term Loans shall constitute a single Class and a single Borrowing of Amendment No. 3 Term Loans for all purposes under the Amended Credit Agreement.

Section 2.4. Lenders. The New Incremental Term Lender acknowledges and agrees that, upon its execution of this Agreement and the effectiveness of its New Incremental Term Loan Commitment,

the New Incremental Term Lender shall become a “Lender” under, and for all purposes of, the Amended Credit Agreement and the other Loan Documents, and shall be subject to and bound by the terms thereof, and shall perform all the obligations of

and shall have all rights of a Lender thereunder.

Section 2.5. Taxes. For U.S. federal income tax purposes, the Existing Term Loans and the New Incremental Term Loans will be treated as a single issue of debt instruments.

Section 2.6. Acknowledgments.

The Administrative Agent and the New Incremental Term Lender each hereby expressly consent to this Amendment and all amendments to the Existing Credit

Agreement set forth herein. Each of the parties hereto agree that (i) the New Incremental Term Loans constitute Incremental Term Loans, (ii) the Acquisition constitutes a Limited Condition Transaction, (iii) the Borrower has made an LCA Election and

the LCA Test Date is April 21, 2026, in each case, with respect to the Acquisition (such date, the “Acquisition LCA Test Date”), (iv) this Amendment constitutes an Incremental

Facility Amendment, (v) this Amendment shall satisfy any requirement under Section 2.18(1) of the Existing Credit Agreement to deliver a notice to the Administrative Agent in connection with the establishment of the New Incremental Term Loans, and

(vi) the New Incremental Term Loans are being incurred pursuant to the Incremental Ratio Amount.

ARTICLE III

[reserved]

ARTICLE IV

Conditions to Effectiveness

Section 4.1. Amendment No. 4 Effective Date

This Amendment shall be legal, valid and binding on and as of the date hereof and the amendments and waivers implemented pursuant to the terms hereof

shall become effective immediately at such time that the following conditions has been satisfied or waived (the “Amendment No. 4 Effective Date”):

(a) (Credit Documents) The Administrative Agent shall have received duly executed counterparts of this Amendment, which shall constitute a signature page and counterpart hereto that,

when taken together, bear the signatures of (A) the Borrower, (B) each Guarantor, (C) the Administrative Agent, and (D) the New Incremental Term Lender;

(b) (Secretary’s Certificate) The Administrative Agent shall have received a certificate from each Loan Party (or the Borrower on behalf thereof), dated on the Amendment No. 4

Effective Date, signed by the Secretary or Assistant Secretary of such Loan Party (or the Borrower on behalf thereof), and attested to by a Responsible Officer of such Loan Party (or the Borrower on behalf thereof), together with (I) either (x)

copies of the certificate or articles of incorporation and by-laws (or equivalent organizational documents), as applicable, of such Loan Party or (y) a certification by the Secretary or Assistant Secretary of such Loan Party that the copies of

the certificate or articles of incorporation and by-laws (or equivalent organizational documents), as applicable, of such Loan Party delivered to the Administrative Agent on November 14, 2023 or February 2, 2026 remain in full force and effect

and have not been modified or amended since such prior delivery, (II) the resolutions of such Loan Party referred to in such certificate approving this Amendment and the transactions contemplated hereby, and of all documents evidencing other

necessary corporate action, if any, with respect to this Amendment and the transactions contemplated hereby, and (III) a certification as to the names and true signatures of the officers of such Loan Party authorized to sign this Amendment and

the other documents to be delivered hereunder, and each of the foregoing shall be in customary form;

(c) (Closing Certificate) The Administrative Agent shall have received a certificate from a Responsible Officer of the Borrower, dated the Amendment No. 4 Effective Date, to the

effect that (i) as of the Acquisition LCA Test Date, no Specified Event of Default shall have occurred and be continuing or would result from the transactions contemplated hereby and (ii) the Specified Representations are true and correct in all

material respects as of the Acquisition LCA Test Date (except, to the extent that such representations and warranties specifically refer to an earlier date, they are true and correct in all material respects as of such earlier date); provided that, to the extent that such representations and warranties are qualified by materiality, material adverse effect or similar language, they are true and correct in

all respects;

(d) (Incremental Amount Certificate) The Administrative Agent shall have received a certificate from a Responsible Officer of the Borrower, dated as of the Amendment No. 4

Effective Date, certifying as to the calculation of the Incremental Amount as of the Acquisition LCA Test Date and calculated in accordance

with Sections 1.08 and 1.09 of the Amended Credit Agreement.

(e) (Solvency Certificate) The Administrative Agent shall have received a solvency certificate from the chief financial officer or another officer with equivalent duties of the

Borrower on the Amendment No. 4 Effective Date after giving effect to all of the transactions contemplated hereby, substantially in the form of Exhibit B to the Amended Credit Agreement;

(f) (Legal Opinions) The Administrative Agent shall have received from Brown Rudnick LLP, special New York counsel to the Loan Parties, written opinions in form and substance

reasonably satisfactory to the Administrative Agent dated the Amendment No. 4 Effective Date;

(g) (Fees and Costs) The Borrower shall have paid on or prior to the Amendment No. 4 Effective Date, or will pay substantially concurrently with the occurrence of the Amendment No. 4

Effective Date, without duplication, (i) to the extent agreed in writing, all reasonable and documented costs and expenses of the Administrative Agent and the Amendment No. 4 Lead Arrangers incurred in connection with this Amendment and the

transactions contemplated hereby (including, without limitation, the reasonable and documented fees, charges and disbursements of Paul Hastings LLP, counsel to the Administrative Agent and the Amendment No. 4 Lead Arrangers) and any other fees,

agreed in writing to be payable to the Amendment No. 4 Lead Arrangers on the Amendment No. 4 Effective Date, (ii) all other compensation required to be paid on or prior to the Amendment No. 4 Effective Date to the Amendment No. 4 Lead Arrangers

pursuant to that certain Amended and Restated Engagement Letter, dated as of May 22, 2026, among the Borrower and the Amendment No. 4 Lead Arrangers and (iii) the ticking fees and upfront fees, if any, agreed with the Lead Left Amendment No. 4

Arranger and communicated to the prospective New Incremental Term Lenders in connection with the primary syndication of the New Incremental Term Loans;

(h) (Borrowing Request). The Administrative Agent shall have received a Borrowing Request requesting the borrowing of the New Incremental Term Loans;

(i) (KYC; Beneficial Ownership). The Administrative Agent shall have received, at least five days prior to the Amendment No. 4 Effective Date, all documentation and other

information regarding the Borrower requested in connection with applicable “know your customer” and anti-money laundering rules and regulations, including the USA Patriot Act, to the extent reasonably requested in writing of the Borrower at least

ten days prior to the Amendment No. 4 Effective Date and (ii) to the extent the Borrower qualifies as a “legal entity customer” under the Beneficial Ownership Regulation, at least five days prior to the Amendment No. 4 Effective Date, any Lender

that has requested, in a written notice to the Borrower at least ten days prior to the Amendment No. 4 Effective Date, a Beneficial Ownership Certification in relation to the Borrower shall have received such Beneficial Ownership Certification;

(j) (Acquisition). The Acquisition shall have been consummated, or shall be consummated substantially concurrently with the funding of the New Incremental Term Loans, in

accordance with the terms of the Acquisition Agreement; and

(k) (Amendment No. 4 Effective Date). The Amendment No. 4 Effective Date shall be no later than January 12, 2027.

ARTICLE V

Representations and Warranties

Section 5.1. Representations and Warranties

To induce the Administrative Agent and the New Incremental Term Lender to enter into this Amendment, each Loan Party represents and warrants that, as

of the Acquisition LCA Test Date, both before and after giving effect to the transactions contemplated by this Amendment:

(a) no

Specified Default exists; and

(b) the

Specified Representations of each Loan Party are true and correct in all material respects on and as of such date (except, to the extent that such representations and warranties specifically refer to an earlier date, they are true and correct in

all material respects as of such earlier date); provided that, to the extent that such representations and warranties are qualified by materiality, material adverse effect

or similar language, they are true and correct in all respects.

ARTICLE VI

Miscellaneous

Section 6.1. Effect of Amendment.

(a) On

and after the Amendment No. 4 Effective Date, each reference in the Existing Credit Agreement to “this Agreement”, “hereunder”, “hereof” or words of like import referring to the Existing Credit Agreement, and each reference in the other Loan Documents to the “Credit Agreement”, “thereunder”, “thereof”

or words of like import referring to the Existing Credit Agreement, mean and are a reference to the Credit Agreement as modified by this Amendment. This Amendment is a Loan Document executed pursuant to the Existing Credit Agreement and shall be

construed, administered and applied in accordance with the terms and provisions thereof. Any Loan Document that contains a provision that is inconsistent with the modifications made pursuant to this Amendment, or the transactions provided for

herein, is deemed to be amended in a corresponding manner, or to permit such transactions, as the case may be.

(b) The

Existing Credit Agreement, as specifically amended by this Amendment, is and shall continue to be in full force and effect and is hereby in all respects ratified and confirmed. Without limiting the generality of the foregoing, the Security

Documents and all of the Collateral (after giving effect to this Amendment) do and shall continue to secure the payment of all Obligations that survive this Amendment including without limitation under the Amended Credit Agreement, the Guarantee

and Collateral Agreement and the other Loan Documents.

execution, delivery and effectiveness of this Amendment does not, except as expressly provided herein, operate as a waiver of any right, power or remedy of any Lender or the Administrative Agent under any of the Loan Documents nor constitute a

waiver of any provision of any of the Loan Documents. This Amendment shall not constitute a substitution or novation of the Existing Credit Agreement, the Guarantee and Collateral Agreement or any other Loan Documents.

Section 6.2. Counterparts.

This Amendment may be executed in counterparts (and by different parties hereto on different counterparts), each of which shall constitute an

original, but all of which when taken together shall constitute a single contract. This Amendment constitutes the entire contract among the parties relating to the subject matter hereof and supersedes any and all previous agreements and

understandings, oral or written, relating to the subject matter hereof. This Amendment shall be binding upon and inure to the benefit of the parties hereto and to the other Loan Documents and their respective successors and assigns. This Amendment

may be in the form of an Electronic Record and may be executed using Electronic Signatures (including, without limitation, facsimile and “pdf”) and shall be considered an original, and shall have the same legal effect, validity and enforceability as

a paper record. This Amendment and any document, amendment, approval, consent, information, notice, certificate, request, statement, disclosure or authorization related to this Amendment (each a “Communication”), may be executed in as many counterparts as necessary or convenient, including both paper and electronic counterparts, but all such counterparts are one and the same Amendment. For the avoidance of doubt,

the authorization under this paragraph may include, without limitation, use or acceptance by any of the parties hereto of a manually signed paper Communication which has been converted into electronic form (such as scanned into PDF format), or an

electronically signed Communication converted into another format, for transmission, delivery and/or retention. For purposes hereof, “Electronic Record” and “Electronic Signature” shall have the meanings assigned to them, respectively, by 15 USC § 7006, as it may be amended from time to time.

Section 6.3. GOVERNING LAW; WAIVER OF JURY TRIAL; JURISDICTION; CONSENT TO SERVICE OF PROCESS

THIS AMENDMENT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAW OF THE STATE OF NEW YORK. The provisions of Sections 10.07, 10.11 and

10.15 of the Existing Credit Agreement are incorporated herein and apply to this Amendment, mutatis mutandis.

Section 6.4. Headings.

Article and Section headings used herein are for convenience of reference only, are not part of this Amendment and are not to affect the construction

of, or be taken into consideration in interpreting, this Amendment.

Section 6.5. Reaffirmation.

Each Loan Party hereby expressly acknowledges the terms of this Amendment and reaffirms, as of the date hereof, (a) other than to the extent expressly

set forth herein, the covenants and agreements contained in each Loan Document to which it is a party, including, in each case, such covenants and agreements as in effect immediately after giving effect to this Amendment and the transactions

contemplated hereby and (b) its guarantee of the Obligations under the Guarantee and Collateral Agreement, and its prior grant of security interest and pledge under the Security Documents and each Loan Document and confirms that, other than to the

extent expressly set forth herein, the Liens on the Collateral, security interests and pledges granted pursuant to the Security Documents and each Loan Document continue in full force and effect after giving effect to this Amendment and secure the

Obligations, including without limitation, any additional Obligations resulting from or incurred pursuant to the Amended Credit Agreement.

Section 6.6. Amendment No. 4 Lead Arrangers.

Notwithstanding any other provision of this Amendment or any provision of the Amended Credit Agreement or any other Loan Document, each Lead Arranger

is named as such herein for recognition purposes only, and in its capacity as such shall have no duties, responsibilities or liabilities with respect to this Amendment, the Amended Credit Agreement or any other Loan Document. Without limitation of

the foregoing, the Amendment No. 4 Lead Arrangers in their respective capacities as such shall not, by reason of this Amendment, the Amended Credit Agreement or any other Loan Document, have any fiduciary relationship in respect of any Lender, any

Loan Party or any other Person.

[Signature pages follow]

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed and delivered by their respective duly authorized officers as of the

date first above written.

(signature pages follow)

AMNEAL PHARMACEUTICALS LLC, as Borrower

By:

/s/ Anastasios Konidaris

Name:

Anastasios Konidaris

Title:

Executive Vice President and Chief Financial Officer

AMNEAL BIOSICENCES LLC

AMNEAL PHARMACEUTICALS OF NEW YORK, LLC

GEMINI LABORATORIES, LLC

IMPAX LABORATORIES, LLC

AMEDRA PHARMACEUTICALS LLC

TRAIL SERVICES, LLC,

each as a Guarantor

By:

/s/ Anastasios Konidaris

Name:

Anastasios Konidaris

Title:

Executive Vice President and Chief Financial Officer

[Signature Page to Amendment No. 4 to Term Loan Credit Agreement]

JPMORGAN CHASE BANK, N.A., as Administrative Agent

By:

/s/ William R. Doolittle

Name:

William R. Doolittle

Title:

Executive Director

[Signature Page to Amendment No. 4 to Term Loan Credit Agreement]

BANK OF AMERICA, N.A., as the New Incremental Term Lender

By:

/s/ Lex Maultsby

Name:

Lex Maultsby

Title:

Managing Director

[Signature Page to Amendment No. 4 to Term Loan Credit Agreement]

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: ef20079825_ex99-1.htm · Sequence: 4

Exhibit 99.1

Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader

Establishes an integrated global platform spanning biosimilar R&D, manufacturing and commercialization

Adds a major long-term growth pillar and extends Amneal’s growth profile into the 2030s

BRIDGEWATER, N.J., August 10, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the

completion of its acquisition of Kashiv BioSciences, LLC (“Kashiv”), creating a fully integrated global biosimilars leader with end-to-end capabilities across research, development, manufacturing and commercialization. The combination establishes

one of the industry’s few fully integrated biosimilars platforms.

“The completion of this acquisition marks a pivotal step in Amneal’s strategy to become America’s #1 Affordable Medicines company,” said Chirag Patel,

Co-Founder and Co-Chief Executive Officer. “With this acquisition, we have created an integrated biosimilars business that can launch multiple biosimilars each year and extends our growth profile into the next decade.”

“We are pleased to welcome the Kashiv team to Amneal and thank our shareholders and other stakeholders for their strong support,” said Chintu Patel,

Co-Founder and Co-Chief Executive Officer. “This acquisition helps to position Amneal to capitalize on an unprecedented wave of biologic loss of exclusivity. Together, we will pursue this significant opportunity and work to expand patient access to

high-quality, affordable biologic medicines.”

Strategic Combination

The acquisition combines Kashiv’s biologics research, development and manufacturing capabilities with Amneal’s commercial scale, establishing

biosimilars as a major long-term growth pillar within the Company’s Affordable Medicines business. The transaction provides Amneal access to the global biosimilars market with more than $300 billion projected global biologics loss-of-exclusivity over

the next decade. The combined portfolio is expected to support a consistent cadence of biosimilar launches for years to come.

Integration and Next Steps

The transaction builds on a relationship between Amneal and Kashiv spanning more than a decade, providing a strong foundation for integration.

Integration planning and related activities are underway and are focused on combining the companies’ development and manufacturing capabilities and advancing the biosimilar pipeline.

Goldman Sachs & Co. LLC served as financial advisor and Richards, Layton & Finger, P.A. served as legal counsel to the Committee of Independent

Directors of the Board of Directors. Simpson Thacher & Bartlett LLP served as legal counsel, among other financial and compliance advisors, to Amneal.

J.P. Morgan Securities LLC served as financial advisor, Holland & Knight LLP served as legal counsel, and Dhinal Shah Associates served as an

advisor in India to Kashiv.

About Amneal

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on

expanding access to affordable and innovative medicines. Amneal was founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, and built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing

portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and

biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional

customers. For additional information, please visit amneal.com and follow us on LinkedIn.

About Kashiv BioSciences

Kashiv BioSciences, LLC is a vertically integrated biopharmaceutical company with numerous commercial and advanced clinical-stage assets and is among

the few U.S.-based companies to both manufacture and receive marketing authorization for multiple biosimilars. Kashiv BioSciences, LLC in the U.S., together with its subsidiaries in India (collectively, “Kashiv BioSciences”) operates with robust

infrastructure and highly skilled teams that provide global R&D, clinical, manufacturing, regulatory, and IP capabilities. Kashiv BioSciences believes that its people, partners, and shared purpose fuel its work to advance patient care and access

to important medicines. For additional information, please visit kashivbiosciences.com and follow Kashiv BioSciences on LinkedIn.

Cautionary Statement on Forward-Looking Statements

Certain statements contained herein, regarding matters that are not historical facts,

may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or

forecasts for the future, including among other things: our growth profile; our ability to obtain approval for and launch biosimilars and the frequency of such launches; our ability to become America’s #1 Affordable Medicines company; our ability

to capitalize on losses of exclusivity; our ability to expand patient access to medicines; our integration prospects; our ability to create value for our shareholders; and other non-historical statements. Words such as “plans,” “expects,” “will,”

“anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements.

The reader is cautioned not to rely on these forward-looking statements. These

forward-looking statements are based on current expectations of future events, including with respect to future market conditions, company performance and financial results, operational investments, business prospects, new strategies and growth

initiatives, the competitive environment, our integration of research, development, manufacturing and commercialization capabilities, and

other events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company.

Such risks and uncertainties include, but are not limited to: our ability to successfully integrate Kashiv; our ability to successfully develop,

license, acquire, obtain approval for and commercialize new products on a timely basis; the competition we face in the pharmaceutical and biologics industry from brand and generic product companies, and the impact of that competition on our ability

to set prices; our ability to obtain exclusive marketing rights for our products; the impact of illegal distribution and sale by third parties of counterfeit versions of our products or stolen products; the impact of negative market perceptions of us

and the safety and quality of our products; our revenues are derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers; the continuing trend of consolidation of certain customer

groups; the impact of supply chain disruption; the imposition of tariffs may adversely affect our business, results of operations and financial condition; a U.S. government shutdown could adversely impact our regulatory, operational and financial

performance; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; our dependence on information technology systems and infrastructure and the potential for cybersecurity incidents, and

risks associated with artificial intelligence; the impact of a prolonged business interruption within our supply chain; our ability to attract, hire and retain highly skilled personnel; risks related to federal regulation of arrangements between

manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of claims brought against us by third

parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to government contracting, healthcare fraud abuse, most-favored nation pricing policies, government price controls, and health information

privacy and security and changes in such laws; changes to Food and Drug Administration product approval requirements and review processes; the impact of healthcare reforms and changes in coverage and reimbursement levels and funding by governmental

authorities and other third-party payers, including increases in the number of uninsured individuals and the impact of the expiration of enhanced premium tax credits and subsidies for eligible households that enroll in qualified health plans offered

in Patient Protection and Affordable Care Act health insurance exchanges; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; our dependence on third-party agreements

for a portion of our product offerings; our potential expansion into additional international markets subjecting us to increased regulatory, economic, social and political uncertainties; the impact of global economic, political or other catastrophic

events; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our obligations under a tax receivable agreement

may be significant; and the high concentration of ownership of our Class A common stock by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to

time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned

not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such

statements to reflect the occurrence of events or circumstances after the date hereof.

Investor Contact

Anthony DiMeo

VP, Investor Relations

anthony.dimeo@amneal.com

Media Contact

Brandon Skop

Sr. Director, Corporate Communications

brandon.skop@amneal.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Document and Entity Information

Aug. 10, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 10, 2026

Entity File Number

001-38485

Entity Registrant Name

AMNEAL PHARMACEUTICALS, INC.

Entity Central Index Key

0001723128

Entity Incorporation, State or Country Code

Entity Tax Identification Number

93-4225266

Entity Address, Address Line One

400 Crossing Blvd

Entity Address, City or Town

Bridgewater

Entity Address, State or Province

Entity Address, Postal Zip Code

08807

City Area Code

908

Local Phone Number

947-3120

Title of 12(b) Security

Class A Common Stock, par value $0.01 per share

Trading Symbol

AMRX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration